1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
6
Rare Diseases
across 13 areas
0
News (30d)
Quiet
Ellodi Pharmaceuticals is a company with 1 orphan drug designation across 6 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| adult pulmonary Langerhans cell histiocytosis | fluticasone propionate | Des.TrialAppr. |
| adult-onset non-insulinoma persistent hyperinsulinemic hypoglycemia | fluticasone propionate | Des.TrialAppr. |
| dermatomyositis | fluticasone propionate | Des.TrialAppr. |
| pediatric hepatocellular carcinoma | fluticasone propionate | Des.TrialAppr. |
| pediatric ovarian dysgerminoma | fluticasone propionate | Des.TrialAppr. |
| pediatric-onset Graves disease | fluticasone propionate | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
82
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
82
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
0
affecting portfolio